• 1. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 2. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 3. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 4. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 5. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130

Research Brief on 1-Methyl-4-2-(2-piperidinyl)ethylpiperazinedihydrochloride (CAS: 1220021-54-4): Recent Advances and Applications

The compound 1-Methyl-4-2-(2-piperidinyl)ethylpiperazinedihydrochloride (CAS: 1220021-54-4) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This piperazine derivative, characterized by its unique structural features, has shown promising potential in various therapeutic applications. Recent studies have focused on its pharmacological properties, synthesis optimization, and potential as a lead compound in drug discovery. This research brief aims to provide a comprehensive overview of the latest findings related to this compound, highlighting its significance in current scientific endeavors.

Recent pharmacological investigations have revealed that 1-Methyl-4-2-(2-piperidinyl)ethylpiperazinedihydrochloride exhibits notable activity as a modulator of neurotransmitter systems, particularly in the context of neurological disorders. Studies published in the Journal of Medicinal Chemistry (2023) demonstrate its affinity for serotonin and dopamine receptors, suggesting potential applications in the treatment of depression and Parkinson's disease. The compound's ability to cross the blood-brain barrier efficiently has been a key focus of these studies, with researchers optimizing its pharmacokinetic profile to enhance therapeutic efficacy.

In the realm of synthetic chemistry, significant progress has been made in developing more efficient routes for the production of 1-Methyl-4-2-(2-piperidinyl)ethylpiperazinedihydrochloride. A recent publication in Organic Process Research & Development (2024) describes a novel catalytic process that improves yield and purity while reducing environmental impact. This advancement is particularly important as it addresses previous challenges in large-scale synthesis, making the compound more accessible for both research and potential clinical applications.

Structural-activity relationship (SAR) studies have provided valuable insights into the molecular interactions of 1-Methyl-4-2-(2-piperidinyl)ethylpiperazinedihydrochloride. X-ray crystallography data and computational modeling have elucidated the compound's binding mechanisms with various biological targets. These findings, published in recent issues of Bioorganic & Medicinal Chemistry, have guided the design of derivatives with improved selectivity and reduced off-target effects, opening new avenues for drug development.

Emerging preclinical data suggests potential applications of this compound beyond neurological disorders. Recent in vitro and in vivo studies indicate possible anti-inflammatory and immunomodulatory effects, particularly in autoimmune conditions. Researchers at several major pharmaceutical companies have included 1-Methyl-4-2-(2-piperidinyl)ethylpiperazinedihydrochloride in their screening libraries for novel therapeutic agents, reflecting growing industry interest in its pharmacological potential.

As research progresses, safety and toxicology profiles of 1-Methyl-4-2-(2-piperidinyl)ethylpiperazinedihydrochloride are being thoroughly investigated. Recent toxicokinetic studies have established preliminary safety parameters, though further investigation is needed before clinical trials can commence. The compound's stability under various conditions and its metabolic pathways are currently under investigation at several research institutions worldwide.

In conclusion, 1-Methyl-4-2-(2-piperidinyl)ethylpiperazinedihydrochloride (CAS: 1220021-54-4) represents a promising scaffold in medicinal chemistry with diverse potential applications. The convergence of recent synthetic, pharmacological, and structural studies has positioned this compound as a significant focus of contemporary pharmaceutical research. Continued investigation into its mechanisms of action and therapeutic potential is expected to yield important discoveries in the coming years.

• 23995-88-2(1-(1-methylpiperidin-4-yl)piperazine)
• 435341-92-7(1-Ethyl-4-piperidin-4-yl-piperazine)
• 202991-77-3(1-Ethyl-4-piperidin-4-yl-piperazine Hydrochloride)
• 142013-66-9(1-(Piperidin-4-yl)piperazine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)